Cargando…
Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure ≥35 mm Hg
Portopulmonary hypertension (POPH), pulmonary arterial hypertension (PAH) that develops in the setting of portal hypertension, affects 5%–6% of patients with liver disease and is associated with significant morbidity and mortality. A mean pulmonary arterial pressure (mPAP) threshold of 35 mm Hg is u...
Autores principales: | DuBrock, Hilary M., Runo, James R., Sadd, Corey J., Burger, Charles D., Cartin-Ceba, Rodrigo, Rosen, Charles B., Taner, Timucin, Nyberg, Scott L., Heimbach, Julie K., Findlay, James Y., Krowka, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665265/ https://www.ncbi.nlm.nih.gov/pubmed/33204828 http://dx.doi.org/10.1097/TXD.0000000000001085 |
Ejemplares similares
-
Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes
por: del Valle, Kathryn T., et al.
Publicado: (2022) -
Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes
por: DuBrock, Hilary M., et al.
Publicado: (2019) -
Causes and Circumstances of Death in Portopulmonary Hypertension
por: Sahay, Sandeep, et al.
Publicado: (2021) -
Influence of Intraoperative Transesophageal Echocardiography and Pulmonary Artery Catheter Monitoring on Outcomes in Liver Transplantation
por: Hofer, Ryan E., et al.
Publicado: (2020) -
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
por: Cartin-Ceba, Rodrigo, et al.
Publicado: (2018)